Use of Reverse Phase Protein Arrays to Identify Biomarkers of Response to PI3K/mTOR Inhibitors in Ovarian Cancer Models

被引：0
|
作者：
Tashkandi, G. [1 ]
Mullen, P. [2 ]
Goltsov, A. [3 ]
Bown, J. L. [3 ]
Harrison, D. J. [2 ]
Langdon, S. P. [1 ]
机构：
[1] Univ Edinburgh, Inst Genet & Mol Med, Div Pathol, Edinburgh, Midlothian, Scotland
[2] Univ St Andrews, Sch Med, St Andrews, Fife, Scotland
[3] Univ Abertay, CRISP, Dundee, Scotland
来源：
JOURNAL OF PATHOLOGY | 2013年 / 231卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [41] G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer
    Yim, Christina Y.
    Bikorimana, Emmanuel
    Khan, Ema
    Warzecha, Joshua M.
    Shin, Leah
    Rodriguez, Jennifer
    Dmitrovsky, Ethan
    Freemantle, Sarah J.
    Spinella, Michael J.
    CELL CYCLE, 2017, 16 (21) : 2146 - 2155
  • [42] Targeting PI3K/mTOR Signaling in Cancer
    Emerling, Brooke M.
    Akcakanat, Argun
    CANCER RESEARCH, 2011, 71 (24) : 7351 - 7359
  • [43] Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
    Wu, Yi-Hui
    Huang, Yu-Fang
    Chen, Chien-Chin
    Huang, Chia-Yen
    Chou, Cheng-Yang
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [44] Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment
    Condorelli, R.
    Andre, F.
    ANNALS OF ONCOLOGY, 2017, 28 (06) : 1167 - 1168
  • [45] Cell death induction end-points to identify new cancer indications with high likelihood of response to dual PI3K/mTOR inhibitors
    Huang, Alan
    Lehar, Joseph
    Pradhan, Elina
    Di Tomaso, Emmanuelle
    Villarroel, Maria
    Hackl, Wolfgang
    Quadt, Cornelia
    Fritsch, Christine
    Weiss, Andreas
    Brachmann, Saskia
    Schlegel, Robert
    Hofmann, Francesco
    Maira, Michel
    CANCER RESEARCH, 2011, 71
  • [46] Response and determinants of cancer cell susceptibility to PI3K inhibitors
    Yu, Ker
    Toral-Barza, Lourdes
    Shi, Celine
    Zhang, Wei-Guo
    Zask, Arie
    CANCER BIOLOGY & THERAPY, 2008, 7 (02) : 307 - 315
  • [47] Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
    Simon P. Langdon
    Charlene Kay
    In Hwa Um
    Michael Dodds
    Morwenna Muir
    Grant Sellar
    Julie Kan
    Charlie Gourley
    David J. Harrison
    Scientific Reports, 9
  • [48] Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
    Langdon, Simon P.
    Kay, Charlene
    Um, In Hwa
    Dodds, Michael
    Muir, Morwenna
    Sellar, Grant
    Kan, Julie
    Gourley, Charlie
    Harrison, David J.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [49] PIK3CA Mutations PREDICT RESPONSE TO PI3K/AKT/mTOR INHIBITORS
    不详
    CANCER DISCOVERY, 2012, 2 (03) : 205 - 205
  • [50] Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
    Sheppard, Karen E.
    Cullinane, Carleen
    Hannan, Katherine M.
    Wall, Meaghan
    Chan, Joanna
    Barber, Frances
    Foo, Jung
    Cameron, Donald
    Neilsen, Amelia
    Ng, Pui
    Ellul, Jason
    Kleinschmidt, Margarete
    Kinross, Kathryn M.
    Bowtell, David D.
    Christensen, James G.
    Hicks, Rodney J.
    Johnstone, Ricky W.
    McArthur, Grant A.
    Hannan, Ross D.
    Phillips, Wayne A.
    Pearson, Richard B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (18) : 3936 - 3944
12345